N@N

TARGACEPT INC (NASDAQ:TRGT), Down By 5.27% ($0.25) From $4.740 After BUYINS.NET Report Predicted Weakness After Earnings

^{Published on 2012-05-14 13:40:47 - WOPRAI}
 

May 14, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, May 2nd 2012 stating that TARGACEPT INC (NASDAQ:TRGT) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=trgt&id=270502

At the time this story was written, TARGACEPT INC (NASDAQ:TRGT) is Down By 5.27% ($0.25) From $4.740 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

TARGACEPT INC (NASDAQ:TRGT) - Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. The companys pipeline of clinical-stage product candidates includes TC-5214, which completed Phase II b clinical trial for treating depressive disorders; AZD3480, which completed Phase II clinical trial in adults with attention deficit/hyperactivity disorder (ADHD) for the treatment of ADHD; AZD1446 that completed multiple Phase I trial for Alzheimers disease and ADHD; TC-5619, which is in Phase II clinical trial targeting cognitive dysfunction in schizophrenia and one or more other conditions characterized by cognitive impairment; and TC-6987, which is in Phase I trial targeting disorders characterized by inflammation. It has collaboration agreements with AstraZeneca AB for the development and commercialization of TC-5214 as a treatment for major depressive disorders; and a strategic alliance with GlaxoSmithKline to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. TARGACEPT INC (NASDAQ:TRGT) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net